Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|March 3, 2015
SGS Adds Amino Acid Analysis at German Facility
Author(s)Pharmaceutical Technology Editors
SGS Life Science Services adds analytical methods to identify amino acid impurities in bio/pharmaceutical manufacturing at facility in Germany.
Advertisement
SGS Life Science Services has announced that it offers analytical methods, in line with the European Pharmacopoeia (Ph.Eur.), to identify amino acid impurities in bio/pharmaceutical manufacturing at its laboratory in Taunusstein, Germany. The facility is the only contract lab in Germany able to offer these services under GMP, the company reports.
Analysis will be conducted in accordance with Ph.Eur. 2.2.56, Method 1 – Post-Column Ninhydrin Derivatisation, which started in January 2014. Ninhydrin is a reagent used to derivatise amino acids and was traditionally tested using thin layer chromatography, combined with visual and qualitative determination. The newer method, outlined in Ph.Eur.’s most recent edition and employed at the SGS facility, utilizes spectrophotometry and liquid chromatographic techniques for greater resolution and sensitivity.
SGS anticipates that qualification will be completed in March 2015, with the amino acid analytical function fully operational by May 2015. The capabilities in Germany complement SGS’ existing amino acid analytical services provided from its laboratories in Clichy, France, Wavre, Belgium, and Lincolnshire, IL.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement